Plant-based biologics are biopharmaceutical products that are produced using plant-based expression platforms such as tobacco plants, algae, moss, or other plant systems instead of the conventional platforms that use mammalian cell cultures or microbial fermentation systems. These plant-based systems offer several advantages over conventional systems including low-cost manufacturing at large-scale, lack of mammalian pathogens, and the ability to conduct human-like post-translational modifications. Major products being developed using plant-based platforms include vaccines, antibodies, and recombinant proteins.
The global plant-based biologics market is estimated to be valued at US$ 19.4 Mn in 2023 and is expected to exhibit a CAGR of 3.4% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
The global plant-based biologics market is driven by the growing adoption of plant-based biologic alternatives due to their advantages over conventional production systems. Factors such as low-cost and large-scale manufacturing using plant-based platforms and lack of need for expensive fermentation and cell culture facilities are promoting research and development activities in this market. Additionally, rising demand for more sustainable and environment-friendly production methods is further fueling the market growth.
The global plant-based biologics market is expected to be flourished by the growing adoption of plant-based alternatives. The heading opportunity refers to adoption of plant-based alternatives due to their advantages over conventional production systems. Major drivers of the market include:
1) Low-cost manufacturing: Plant-based biologics platforms allow for low-cost manufacturing at large-scale which is a major driver as it enables biologics to be affordable. This driver is referred from the heading opportunity of adoption of plant-based alternatives due to their low-cost advantages.
2) Sustainable production: Plant-based systems are more sustainable and environment-friendly compared to conventional microbial fermentation and cell culture methods as they do not require expensive facilities. The growing demand for sustainable production methods further promotes the plant-based biologics market.
The global plant-based biologics market is dominated by the therapeutic sub-segment. Plant-based systems allow the production of complex therapeutic proteins with proper folding and posttranslational modifications, making them an attractive alternative to microbial and animal cell culture systems for manufacturing therapeutic biologics. Mammalian-compatible post-translational modifications and the absence of human pathogens increase the acceptability of plant-made biologics over microbial systems.
Political: Regulations for drug manufacturing and clinical trials are well established in major markets but vary in emerging nations. Support for plant-made biologics from regulatory bodies can stimulate investments.
Economic: The rise of non-communicable diseases and demand for affordable biologics will support market growth. However, high R&D costs may deter entry of small players initially.
Social: As biologics penetrate new therapy areas, acceptance of plant-based production can increase if cost and supply security benefits are realized. Societal focus on environmental sustainability also favors the use of plant systems.
Technological: Advancements in plant molecular farming, targeted protein expression, downstream processing, and analytical techniques aid commercial-scale production. The use of transient expression systems allows rapid clinical-grade manufacturing at lower costs.
The global plant-based biologics market is expected to witness high growth over the forecast period due to the increasing demand for affordable biologics for chronic diseases.
The North American region currently dominates due to presence of major players and supportive regulatory environment. However, the Asia Pacific region is expected to show fastest growth on account of rising healthcare investments, expanding biologics industry, and lower manufacturing costs.
Key players operating in the plant-based biologics market are Leaf Expression Systems, Zea Biosciences, Planet Biotechnology Inc., InVitria, PlantForm Corporation, IBIO, Inc., Mapp
- Source: Coherent Market Insights, Public sources, Desk research
- We have leveraged AI tools to mine information and compile it